Cited 18 time in
- Title
- Epimagnolin A inhibits IL-6 production by inhibiting p38/NF-κB and AP-1 signaling pathways in PMA-stimulated THP-1 cells
- Author(s)
- H W Chun; S J Kim; T H Pham; Y Bak; J Oh; Hyung Won Ryu; Sei-Ryang Oh; J T Hong; D Y Yoon
- Bibliographic Citation
- Environmental Toxicology, vol. 34, no. 7, pp. 796-803
- Publication Year
- 2019
- Abstract
- Epimagnolin A is a lignan obtained from the flower buds of Magnolia fargesii, which is traditionally used in Asian medicine for treating headache and nasal congestion. A herbal compound fargesin obtained from M. fargesii, has exerted anti-inflammatory effects in human monocytic THP-1 cells in the previous study. The anti-inflammatory effects of epimagnolin A, however, have been not elucidated yet. In this study, it was demonstrated that epimagnolin A reduced phorbol-12-myristate-13-acetate (PMA)-induced IL-6 promoter activity and IL-6 production in human monocytic THP-1 cells. Furthermore, it was investigated the modulating effects of epimagnolin A on mitogen-activated protein kinase, nuclear factor-kappa B (NF-κB), and activator protein 1 (AP-1) activities. Phosphorylation of p38 and nuclear translocation of p50 and c-Jun were down-regulated by epimagnolin A in the PMA-stimulated THP-1 cell. The results revealed that epimagnolin A attenuated the binding affinity of NF-κB and AP-1 transcription factors to IL-6 promoter and IL-6 production through p38/NF-kB and AP-1 signaling pathways in the PMA-stimulated THP-1 cells. These results suggest that epimagnolin A can be a useful drug for the treatment of inflammatory diseases.
- Keyword
- activator protein-1anti-inflammatoryEpimagnolin ANF-κBp38 MPAKTHP-1 cells
- ISSN
- 1520-4081
- Publisher
- Wiley
- Full Text Link
- http://dx.doi.org/10.1002/tox.22746
- Type
- Article
- Appears in Collections:
- Ochang Branch Institute > Natural Product Research Center > 1. Journal Articles
Ochang Branch Institute > 1. Journal Articles
- Files in This Item:
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.